samedan logo
 
 
 
spacer
home > ebr > autumn 2017 > homing in
PUBLICATIONS
European Biopharmaceutical Review

Homing In

Since the first daVinci surgical systems began marketing in 1999 and the following acquisition of Computer Motion by Intuitive Surgical in 2003, very few innovations have been made in the field. Initial adoption of such technology was limited and most surgeons were highly sceptical about its future. However, over the span of 15 years, Intuitive Surgical transformed robotic surgery from an interesting market experiment to an established technique. Today, analysts project exponential growth in the years to come, and nobody doubts that the future is in robotics.

As initial patents expire and new technologies are developed, a rising number of modern robotic surgical systems have been, or are about to be, launched. The competition for shares will be fierce.

Perfecting Platforms

The market might seem big enough for everybody, but the reality could be more complex. For most hospitals, adopting a given robotic surgical platform is a big decision and is not easily reversible, as it involves significant costs and efforts, such as staff training. Due to the requirements for an increased number of operating rooms and storage, a costly multi-platform-adapted staff and a complex maintenance organisation, working with two different types of robotic platforms is also unlikely. However, bigger hospitals that might actually need to utilise several robotic platforms could reduce costs by taking advantage of economies of scale.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Andre Faure has a surgical background and decided to interrupt his early medical career to develop new surgical devices. For more than 15 years, he has led several multi-national R&D programmes in the field where he has developed robotic surgical instruments, including devices for treating atrial fibrillation and liver cancer. Andre is also the founder of Trod Medical, a company created around one of his inventions – a robotic device specifically developed for localised prostate cancer treatment.
spacer
Dr Andre Faure
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Owen Mumford Launches New 2-Step Single-Use Auto-Injector Platform Aidaptus®

OXFORD, England, 22nd September - Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd. has launched its new Aidaptus® auto-injector platform following successful completion of development. Aidaptus is a 2-step, spring-powered, single use auto-injector with a versatile design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device. It also features stopper sensing technology with a self-adjusting plunger that automatically adapts to the individual stopper positions and different fill volumes in each syringe, with no change parts required. The auto-injector is available with two different spring strengths to accommodate a variety of drug viscosities.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement